Its activity focuses on the production and development of pMDIs (Asthma and Pulmonary Arterial Hypertension) and oral solids (Cardiovascular, Respiratory and CNS diseases).
In full operation with its 2 production units and with 3 shifts/day it can produce more than 70.000.000 packages annually.
- Regarding pMDIs: It has the capacity to produce more than 35.000.000 packages per year for this specific category.
- Regarding Oral Solids: With the operation of the Oral Solids’ (tablets and capsules) production unit, production in this category will reach 36.000.000 packages per year.
The overall operation of Keratea’s plant complies fully with the European standards for quality and safety GLP and GMP. At our manufacturing site the following pharmaceutical forms are produced:
Technological Excellence
Its machines are fully automated with the ability to produce and pack with 100% automated control throughout their operation. In addition, it has robotic systems and machines that are unique in the Greek market.
The comparative advantage of our new plant is its design and construction. Both were implemented with a focus on reducing the energy footprint in order to contribute effectively to the protection of the environment.
Reduced Environmental Footprint
It is the only plant in Greece whose design has been done from the beginning in a way that provides the capability of using the most modern propellants with low environmental footprint, in accordance with the relevant European guidelines that will soon come into force. The technical peculiarities and the high construction costs of the plant with specifications that allow the safe use of these gases, make it not only the only one in Greece, but also one of the 5 plants in Europe with similar capabilities.
The following services are housed in Keratea’s plant:
- Quality Control Laboratory
- Production & Packaging
- Research and Development Laboratories
Strategic location
